Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02970981 | Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma | completed | Phase 2 | 18 | NYU Langone HealthOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT03711188 | A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma | completed | Phase 2 | 16 | Immodulon Therapeutics LtdINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion(NivoILP) |
| recruiting |
| Phase 1 / Phase 2 |
| 74 |
| Vastra Gotaland RegionOTHER_GOV |
| 2 |
| Apr 25, 2024 |
| clinicaltrials |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | terminated | Phase 1 / Phase 2 | 1 | iOx TherapeuticsINDUSTRY | 3 | Apr 24, 2024 | clinicaltrials |
| NCT05050006 | ITIL-168 in Advanced Melanoma(DELTA-1) | terminated | Phase 2 | 29 | Instil BioINDUSTRY | 3 | Apr 16, 2024 | clinicaltrials |
| NCT02519322 | Neoadjuvant and Adjuvant Checkpoint Blockade | completed | Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT02978443 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | terminated | Phase 2 | 14 | Georgetown UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04899921 | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | terminated | Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06327698 | Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure | not yet recruiting | Phase 2 | 30 | Hunan Cancer HospitalOTHER | 0 | Mar 25, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT05280314 | Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors | recruiting | Phase 2 | 60 | IO BiotechINDUSTRY | 6 | Mar 18, 2024 | clinicaltrials |
| NCT02678741 | Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. | completed | Phase 1 / Phase 2 | 26 | Elios Therapeutics, LLCINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT02159066 | LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma(LOGIC-2) | completed | Phase 2 | 158 | PfizerINDUSTRY | 9 | Mar 5, 2024 | clinicaltrials |
| NCT04879654 | Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery(SNMM) | unknown | Phase 2 | 45 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT00003552 | Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00019396 | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00019448 | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00019890 | Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 0 | Mar 4, 2024 | clinicaltrials |
| NCT00020475 | Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02126579 | Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists(MEL60) | completed | Phase 1 / Phase 2 | 50 | Craig L Slingluff, JrOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04455503 | Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | terminated | Phase 1 / Phase 2 | 15 | Evaxion Biotech A/SINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05060003 | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05135715 | A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) | unknown | Phase 2 | 50 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04337931 | A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma | terminated | Phase 2 | 45 | Apexigen America, Inc.INDUSTRY | 2 | Feb 13, 2024 | clinicaltrials |
| NCT03617328 | Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma(Mel-65) | completed | Phase 1 / Phase 2 | 33 | Craig L Slingluff, JrOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03052127 | Study in Subjects With Small Primary Choroidal Melanoma | completed | Phase 1 / Phase 2 | 57 | Aura BiosciencesINDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05756556 | T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma | suspended | Phase 2 | 68 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06229340 | Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations(NТО-RAS) | recruiting | Phase 2 | 20 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT04242329 | Surgery of Melanoma Metastases After Systemic Therapy(SUMMIST) | withdrawn | Phase 2 | 0 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT00866840 | Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT03850691 | Radiation and Combination Immunotherapy for Melanoma | completed | Phase 2 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03765229 | An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma | completed | Phase 2 | 11 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT04720768 | Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE(CELEBRATE) | unknown | Phase 1 / Phase 2 | 78 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT00979693 | Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma | withdrawn | Phase 2 | 0 | Multidisciplinary Association for Psychedelic StudiesOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03123783 | CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | completed | Phase 1 / Phase 2 | 140 | Apexigen America, Inc.INDUSTRY | 2 | Dec 26, 2023 | clinicaltrials |
| NCT02101008 | Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy | completed | Phase 2 | 12 | University of UtahOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT02697630 | Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye(PEMDAC) | completed | Phase 2 | 29 | Vastra Gotaland RegionOTHER_GOV | 1 | Dec 8, 2023 | clinicaltrials |
| NCT02223819 | Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy | completed | Phase 2 | 34 | Columbia UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04894994 | FLX475 in Combination With Ipilimumab in Advanced Melanoma | terminated | Phase 2 | 6 | RAPT Therapeutics, Inc.INDUSTRY | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04729543 | MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer(MC2TCR) | recruiting | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT06152367 | Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients | completed | Phase 1 / Phase 2 | 90 | University of ChileOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 6 | Arkadiusz Z. Dudek, MDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02557321 | PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma | unknown | Phase 1 / Phase 2 | 50 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT04785365 | Long-Term Follow-Up Study of Patients Receiving ATL001 | terminated | Phase 2 | 1 | Achilles Therapeutics UK LimitedINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02143050 | Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients | withdrawn | Phase 1 / Phase 2 | 0 | University of LouisvilleOTHER | 1 | Nov 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 30, 2024source: clinicaltrials